Thursday, 15 October 2026European Markets

ALTRI SGPS Stock Over 17% Down In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of ALTRI SGPS (PSI: ALTR.LS) dropped by a staggering 17.91% in 5 sessions from €4.97 to €4.08 at 17:21 EST on Monday, after two consecutive sessions in a row of gains. PSI is dropping 0.54% to €6,010.33, after three consecutive sessions in a row of losses.

ALTRI SGPS's last close was €4.14, 39.34% under its 52-week high of €6.83.

About ALTRI SGPS

Altri, SGPS, S.A. produces and sells cellulosic fibers and energy in Portugal and internationally. The company produces pulp products for various application including production of paper, tissue, and printing and writing papers; and dissolving pulp for use of textile production. It is also involved timber commercialization; forest management; production of forest-based renewable energy, such as industrial cogeneration from black liquor and biomass; real estate activities; and production of plants in nurseries, as well as the provision of services related with forests and landscapes. The company was incorporated in 2005 and is headquartered in Porto, Portugal.

Earnings Per Share

As for profitability, ALTRI SGPS has a trailing twelve months EPS of €0.76.

PE Ratio

ALTRI SGPS has a trailing twelve months price to earnings ratio of 5.37. Meaning, the purchaser of the share is investing €5.37 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.22%.

More news about ALTRI SGPS (ALTR.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com